Endocyte Company Profile (NASDAQ:ECYT)

Analyst Ratings

Consensus Ratings for Endocyte (NASDAQ:ECYT) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.50 (290.63% upside)

Analysts' Ratings History for Endocyte (NASDAQ:ECYT)
Show:
DateFirmActionRatingPrice TargetActions
7/12/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016WedbushReiterated RatingOutperform$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2015Royal Bank Of CanadaLower Price TargetOutperform$13.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/8/2015Cantor FitzgeraldReiterated RatingBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/30/2014Brean CapitalDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2014Citigroup Inc.Reiterated RatingNeutral$8.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/25/2014Chardan CapitalReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Endocyte (NASDAQ:ECYT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/4/2016Q116($0.25)($0.24)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2016Q4($0.27)($0.23)$0.01 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.27)($0.24)$0.03 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.30)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.24)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414($0.25)($0.19)$2.55 million$12.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q314($0.21)($0.14)$5.10 million$3.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2014Q214$0.10$0.52$26.62 million$49.17 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2014Q114($0.14)($0.09)$15.07 million$17.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2014Q413($0.14)($0.08)$15.90 million$17.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013($0.06)($0.11)$14.24 million$14.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/15/2013Q413($0.10)$8.50 million$13.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Endocyte (NASDAQ:ECYT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.29)($0.27)($0.28)
Q2 20162($0.29)($0.27)($0.28)
Q3 20162($0.30)($0.29)($0.30)
Q4 20161($0.29)($0.29)($0.29)
Q1 20171($0.32)($0.32)($0.32)
Q2 20171($0.33)($0.33)($0.33)
Q3 20171($0.33)($0.33)($0.33)
Q4 20171($0.34)($0.34)($0.34)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Endocyte (NASDAQ:ECYT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Endocyte (NASDAQ:ECYT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/10/2016Philip S LowInsiderBuy11,375$3.52$40,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Fred A. MiddletonDirectorBuy10,000$2.79$27,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Fred A. MiddletonDirectorBuy20,000$2.80$56,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/9/2014Allen RitterVPSell1,000$21.16$21,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014Allen RitterVPSell8,000$33.11$264,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Philip LowInsiderSell6,000$15.00$90,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013P Ron EllisCEOSell3,000$12.00$36,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Allen RitterVPSell2,000$17.06$34,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2013David MeekInsiderSell10,000$15.50$155,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013P Ron EllisCEOSell3,000$14.54$43,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013Allen RitterVPSell6,000$14.36$86,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/6/2013Chandra LovejoyVPSell7,000$17.29$121,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013P Ron EllisCEOSell3,000$18.12$54,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2013P Ron EllisCEOSell3,000$17.01$51,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Ann HanhamDirectorSell9,900$14.10$139,590.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2013Ann HanhamDirectorSell40,000$14.38$575,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013Ann HanhamDirectorSell37,200$14.41$536,052.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013Binh NguyenVPSell17,300$14.42$249,466.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Ann HanhamDirectorSell40,200$14.69$590,538.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013Christopher P LeamonVPSell5,000$14.70$73,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2013Chandra D LovejoyVPSell2,102$9.70$20,389.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2012Chandra D LovejoyVPSell2,209$9.05$19,991.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2012Chandra D LovejoyVPSell2,209$8.72$19,262.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Endocyte (NASDAQ:ECYT)
DateHeadline
07/27/16 03:53 PMCan Shares Of Endocyte, Inc. (NASDAQ:ECYT) Hit $8? - Investor Newswire
07/22/16 07:16 AMEarnings Focus and Crowd Sourced Sentiment Review for Endocyte, Inc. (NASDAQ:ECYT) - TGP
07/21/16 12:57 PMETF’s with exposure to Endocyte, Inc. : July 21, 2016 -
07/21/16 07:15 AMIs $8 Price Target Attainable For Endocyte, Inc. (NASDAQ:ECYT)? - Investor Newswire
07/20/16 04:58 PMEndocyte Incorporated (NASDAQ:ECYT) Sellers Covered 7.44% of Their Shorts - Consumer Eagle
07/20/16 06:55 AMWere Analysts Bearish Endocyte, Inc. (NASDAQ:ECYT) This Week? - Consumer Eagle
07/19/16 09:52 AMEquity Roundup: Stock Performance Focus on Endocyte, Inc. (NASDAQ:ECYT) - Press Telegraph
07/18/16 03:53 PMShares Moving Down on the Week: Endocyte, Inc. (NASDAQ:ECYT) - Engelwood Daily
07/15/16 10:47 AMEndocyte Incorporated (NASDAQ:ECYT) Shorted Shares Decreased By 8.99% - Press Telegraph
07/15/16 10:47 AMInsiders Increasing Positions in: Endocyte, Inc. (NASDAQ:ECYT) - Press Telegraph
07/15/16 10:47 AMCrowd Rating and Earnings Recap for Endocyte, Inc. (NASDAQ:ECYT) - Telanagana Press
07/14/16 04:40 AMEndocyte, Inc. (NASDAQ:ECYT) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/14/16 04:40 AMStrong Sell Calls For Endocyte, Inc. (NASDAQ:ECYT) At 0 - Investor Newswire
07/13/16 03:57 PMEarnings Check and Company Target Review for Endocyte, Inc. (NASDAQ:ECYT) - Press Telegraph
07/12/16 08:04 AMTrading Performance and Target Watch for Endocyte, Inc. (NASDAQ:ECYT) - Press Telegraph
07/11/16 03:47 PMNext Weeks Broker Price Targets For Endocyte, Inc. (NASDAQ:ECYT) - Fiscal Standard
07/11/16 08:34 AMCompany Stock Focus for Endocyte, Inc. (NASDAQ:ECYT): Which Way Will Shares Head? - Press Telegraph
07/08/16 07:39 AMNew Broker Ratings For Endocyte, Inc. (NASDAQ:ECYT) - FTSE News
07/08/16 07:39 AMWall Street Ratings and Target Price Views on Endocyte, Inc. (NASDAQ:ECYT) - Telanagana Press
07/07/16 07:34 AMEndocyte, Inc. (NASDAQ:ECYT) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/06/16 03:50 PMCan Endocyte, Inc. (NASDAQ:ECYT) Improve on the Earnings Front? - Engelwood Daily
07/06/16 03:50 PMEndocyte, Inc. (NASDAQ:ECYT) Expected to Reach Highs Of $8 - Investor Newswire
07/06/16 03:50 PMStock Rating Watch and Earnings Insight for Endocyte, Inc. (NASDAQ:ECYT) - Press Telegraph
07/06/16 08:30 AMAdding Up The Components: Russell 2000 Could Rise 15%
07/04/16 08:36 AMWere Analysts Bullish Endocyte, Inc. (NASDAQ:ECYT) This Week? - Press Telegraph
07/01/16 08:11 AMBrokers Issue Average Price Target Of 11.64 On Endocyte, Inc. (NASDAQ:ECYT) - Fiscal Standard
06/30/16 07:43 AMShare Update and Earnings Review for Endocyte, Inc. (NASDAQ:ECYT) - Press Telegraph
06/30/16 07:43 AMEndocyte, Inc. (NASDAQ:ECYT) Company Rating and Target Watch - Telanagana Press
06/30/16 07:43 AMEndocyte Incorporated (NASDAQ:ECYT) Short Interest Decreased By 8.99% - Engelwood Daily
06/30/16 07:43 AMStrong Sell Calls Recommendations For Endocyte, Inc. (NASDAQ:ECYT) At 0 - Investor Newswire
06/29/16 08:43 PMWatching Stock Volatility for: Endocyte, Inc. (NASDAQ:ECYT) - Engelwood Daily
06/29/16 07:42 AMEndocyte Inc. (ECYT) Jumps 7.17% on June 28 - Equities.com
06/23/16 06:44 AMEndocyte, Inc. (NASDAQ:ECYT) Updated Price Targets - FTSE News
06/22/16 08:56 PMStrong Buy Calls Count For Endocyte, Inc. (NASDAQ:ECYT) At 2 - Investor Newswire
06/22/16 03:52 PMEndocyte, Inc. (NASDAQ:ECYT) Stock Momentum Hits Weakness - CML News
06/22/16 08:26 AMStock in the Spotlight: Endocyte, Inc. (NASDAQ:ECYT) - iStreetWire
06/21/16 03:33 PMShining on Major News: Endocyte, Inc. (NASDAQ:ECYT), Celgene Corporation (NASDAQ:CELG), ePlus inc. (NASDAQ ... - KC Register
06/20/16 03:40 PMEndocyte Announces A Change at The Top
06/20/16 03:40 PMEndocyte (ECYT) Names Mike Sherman as President, CEO
06/20/16 09:59 AMStock Update (NASDAQ:ECYT): Endocyte, Inc. Appoints Mike Sherman as President and Chief Executive Officer - Smarter Analyst
06/20/16 08:09 AMEndocyte Appoints Mike Sherman as President and Chief Executive Officer - [at noodls] - WEST LAFAYETTE, Ind., June 20, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized ...
06/20/16 07:53 AMENDOCYTE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
06/20/16 07:46 AM8:46 am Endocyte CFO/COO Mike Sherman appointed as CEO, succeeding Ron Ellis, who resigned effective immediately -
06/19/16 03:32 PMThis Weeks Broker Views For Endocyte, Inc. (NASDAQ:ECYT) - Fiscal Standard
06/16/16 08:58 PMTrend Of Rating Given To Endocyte, Inc. (NASDAQ:ECYT) - Investor Newswire
06/08/16 08:31 AMEndocyte Inc. (ECYT) is Trading Lower on Unusual Volume for June 06 - Equities.com
06/05/16 08:35 AMEndocyte, Inc. (ECYT) Given Outperform Rating at Wedbush - Let Me Know About This
06/04/16 09:05 PMEndocyte, Inc. (ECYT) Given “Buy” Rating at Cowen and Company - Let Me Know About This
06/03/16 03:56 PMBuy, Sell Or Hold Rating For Endocyte, Inc. (NASDAQ:ECYT)? - Share Trading News
06/01/16 10:02 PMEndocyte, Inc. (NASDAQ:ECYT) Stock Update & Estimates - Stock Tick Tock - Endocyte, Inc. (NASDAQ:ECYT) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Endocyte, Inc. (NASDAQ:ECYT) to post earnings of $-0.27 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...and more »

Social

About Endocyte

Endocyte logoEndocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: ECYT
  • CUSIP: 29269A10
Key Metrics:
  • Previous Close: $3.20
  • 50 Day Moving Average: $3.35
  • 200 Day Moving Average: $3.42
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $134.89M
  • Beta: 1.38
  • Current Year EPS Consensus Estimate: $-1.10 EPS
  • Next Year EPS Consensus Estimate: $-1.22 EPS
Additional Links:
Endocyte (NASDAQ:ECYT) Chart for Thursday, July, 28, 2016